Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1477 articles with Gilead Sciences, Inc.
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets
The focus will be on discovering drugs that use the body’s natural protein control processes.
AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.
At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.
Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment
HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences
HitGen Inc. announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kite, a Gilead Company, and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company’s senior leadership team.
Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)
Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.m. Eastern Time.
5/13/2019Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.
The company is pledging to support a goal to end HIV in the U.S. by 2030 announced by the president during the State of the Union this year.
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
Donation Provides up to 2.4 Million Free Bottles Annually to Uninsured Americans at Risk for HIV
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc.
Under the terms of the deal, Gilead holds exclusive options to license worldwide rights to specific products directed toward targets coming out of Goldfinch’s proprietary Kidney Genome Atlas.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14
Webcast Available Through Gilead Corporate Website
Despite continued slumps in sales of its hepatitis C medications, Gilead Sciences saw a robust first quarter, with earnings up nearly 28 percent. That was good news as new Chief Executive Officer Dan O’Day marked his first full quarter with the California-based company.
The dividend is payable on June 27, 2019, to stockholders of record at the close of business on June 14, 2019.